- Home
- MITQ vs PHIO Comparison
MITQ vs PHIO Comparison
Compare MITQ & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- PHIO
- Stock Information
- Founded
- MITQ N/A
- PHIO 2011
- Country
- MITQ United States
- PHIO United States
- Employees
- MITQ N/A
- PHIO N/A
- Industry
- MITQ Telecommunications Equipment
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- MITQ Telecommunications
- PHIO Health Care
- Exchange
- MITQ Nasdaq
- PHIO Nasdaq
- Market Cap
- MITQ 13.4M
- PHIO 12.1M
- IPO Year
- MITQ 2021
- PHIO N/A
- Fundamental
- Price
- MITQ $0.64
- PHIO $1.31
- Analyst Decision
- MITQ
- PHIO Strong Buy
- Analyst Count
- MITQ 0
- PHIO 3
- Target Price
- MITQ N/A
- PHIO $10.67
- AVG Volume (30 Days)
- MITQ 78.3K
- PHIO 8.6M
- Earning Date
- MITQ 11-14-2025
- PHIO 11-13-2025
- Dividend Yield
- MITQ N/A
- PHIO N/A
- EPS Growth
- MITQ N/A
- PHIO N/A
- EPS
- MITQ N/A
- PHIO N/A
- Revenue
- MITQ $18,477,000.00
- PHIO N/A
- Revenue This Year
- MITQ N/A
- PHIO N/A
- Revenue Next Year
- MITQ N/A
- PHIO N/A
- P/E Ratio
- MITQ N/A
- PHIO N/A
- Revenue Growth
- MITQ N/A
- PHIO N/A
- 52 Week Low
- MITQ $0.50
- PHIO $0.97
- 52 Week High
- MITQ $1.66
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- MITQ 36.64
- PHIO 22.08
- Support Level
- MITQ $0.71
- PHIO $1.50
- Resistance Level
- MITQ $0.90
- PHIO $4.19
- Average True Range (ATR)
- MITQ 0.09
- PHIO 0.30
- MACD
- MITQ -0.02
- PHIO -0.04
- Stochastic Oscillator
- MITQ 23.28
- PHIO 0.00
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.